Bristol OTC Pravachol Study Enrollment Does Not Match Indication - FDA

Bristol-Myers Squibb may need to better demonstrate consumers' ability to make self-selection choices based on appropriate cholesterol levels in order to convince FDA that an OTC version of Pravachol is approvable.